Page last updated: 2024-11-13

pf-05231023

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PF-05231023: consists of a humanized monoclonal antibody linked to two molecules of (des-His1,Ala129Cys)FGF21 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57654311
SCHEMBL ID4400652
MeSH IDM000613734

Synonyms (19)

Synonym
SCHEMBL4400652
AC-31459
HY-113697
CS-0063000
mal-amido-peg2-c2-amido-ph-c2-co-azd
1037589-69-7
pf-05231023
3-(2,5-dioxopyrrol-1-yl)-n-[2-[2-[3-oxo-3-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]propoxy]ethoxy]ethyl]propanamide
3-(2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)-n-(2-(2-(3-oxo-3-((4-(3-oxo-3-(2-oxoazetidin-1-yl)propyl)phenyl)amino)propoxy)ethoxy)ethyl)propanamide
EX-A3150
dkl4esk12f ,
1h-pyrrole-1-propanamide, 2,5-dihydro-2,5-dioxo-n-(2-(2-(3-oxo-3-((4-(3-oxo-3-(2-oxo-1-azetidinyl)propyl)phenyl)amino)propoxy)ethoxy)ethyl)-
pf-05231023 crosslinking agent
unii-dkl4esk12f
2,5-dihydro-2,5-dioxo-n-(2-(2-(3-oxo-3-((4-(3-oxo-3-(2-oxo-1-azetidinyl)propyl)phenyl)amino)propoxy)ethoxy)ethyl)-1h-pyrrole-1-propanamide
D87156
MS-29782
pf 5231023
AKOS040742395

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Here we report PF-05231023, a long-acting FGF21 analogue which is unique in that the half-life and subcutaneous (s."( Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
Bernardo, B; Brenner, MB; Calle, R; Chabot, JR; Logan, A; Talukdar, S; Vage, C; Weng, Y; Yan, Q; Zhu, Y, 2015
)
0.97
" Physiologically based pharmacokinetic models incorporating serum stability data and an extravascular extraction term based on differential bioavailability of intact NT and CT of FGF21 in monkeys improved accuracy of human PK predictions relative to Dedrick scaling."( Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Calle, RA; Giragossian, C; Li, J; Liras, J; Logan, A; Pelletier, K; Piché-Nicholas, N; Rajadhyaksha, M; Vage, C; Weng, Y, 2015
)
0.64

Bioavailability

ExcerptReferenceRelevance
") bioavailability of the intact C-terminus are significantly different from those of the intact N-terminus (2 vs."( Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
Bernardo, B; Brenner, MB; Calle, R; Chabot, JR; Logan, A; Talukdar, S; Vage, C; Weng, Y; Yan, Q; Zhu, Y, 2015
)
0.62
" Intact CT of FGF21 displayed approximately 5-fold faster systemic plasma clearance (CL), an approximately 2-fold lower steady-state volume of distribution, and at least 5-fold lower bioavailability compared with NT."( Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Calle, RA; Giragossian, C; Li, J; Liras, J; Logan, A; Pelletier, K; Piché-Nicholas, N; Rajadhyaksha, M; Vage, C; Weng, Y, 2015
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (90.91)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.17 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (27.27%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]